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Abstract: The aim of our study is the integration of a multidisciplinary approach for Prader- Willi and Angelman 
syndromes; distinct genomic diseases; with a neurodegenerative component. The main lesion is localized on the 
15q11.2-13 chromosome caused during genitors' gametogenesis and reproduction process. This deficiency may be 
represented by deletion; uniparental disomy and altered epigenetic marking through DNA methylation or chromatin 
modification. Both diseases are caused by changes in parent contributions on the aforementioned region. The 
modifications in imprinting diseases like Prader Willi and Angelman; require: the study of regional regulation for 
genetic/epigenetic processes in clusters; the contribution of specific genes regulating the imprinting of cluster formation; 
enhancer activity; the DNA and chromatin replication timing; as well as correspondence between histones; protein 
complexes; iRNA and epigenetic processes from DNA. Materials and Methods. The study envisages the cytogenetic 
and molecular genetics approaches in the syndromes diagnosis; establishing a European research network partnership. 
The research will enable: 1. establishment of a strategy in definition for genotypes PWS/AS; 2. correct identification of 
the genetic defect; 3. desciphering the variation in gene expression/ gene subsequention and their regulation pathway 
mechanism; 4.the involvement of epigenetic factors that modulate (enhancing/decreasing) the severity of phenotypic 
aspects into the diagnosis protocols. The study envisages the understanding of early development processes and 
hopefully will contribute to elucidate the basic mechanisms determining the clinical classical modifications. Creation of 
a database will permit the collection of clinical; genetic and epigenetic data from Romania and further the integration 
into the European data base. Results. Due to high mortality and morbidity associated with PSW/AS; this study will be 
the ground for new clinical studies to establish guidelines for diagnosis and treatment in order to improve the quality of 
medical practice and an improvement of medical and social standard for affected patients with PWS/AS. The Romanian 
PWS association is involved in PC 6 (The European Prader-Willi Syndrome Clinical and Basic Science Research); 
project that identifies and pulls together different national teams involved in these topics. The medical research in rare 
genetic disease supposes to be multicentric and even international due to the limitted number of cases. To avoid 
bias we need large series of patients; to assure statistically correct answers necessary for developing international 
good practice standards. Conclusion. The research from Romania should be more active in the rare disease area; 
that's why we propose an epigenetic new European approach realized by prestigious teams. Through this new type 
of partnership between universities; research institutes; hospitals; nongovernmental associations of affected 
patients we try to redefine connections between fundamental research and the medical practice; developing a 
multidisciplinary investigation model for rare disease in Romania. Our study benefits of the applicative research 
experience of some research teams from the Faculty of Biology in Bucharest and The National Institute of 
Virology. Research on animals brings many benefits to human medicine and has a decisive role in understanding 
the etiological mechanisms of some diseases. 
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INTRODUCTION 
 
Prader Willi and Angelman are two distinct genomic diseases; with a 
neurodegenerative component. The main lesion is localised on the 15q11.2- 13 chromosome; 
caused during the genitors’ gametogenesis and reproductive reproduction process (1). This 
deficiency may be represented by deletion; uniparental disomy and altered epigenetic 
marking through DNA methylation or chromatin modification. Both diseases are caused by 
changes in parent contributions on the aforementioned region. The modifications in 
imprinting disease like Prader Willi and Angelman require: the study of regional regulation 
for genetic or epigenetic processes in cluster formation; enhancer activity; the DNA and 
chromatin replication timing; as well as correspondence between histones; protein 
complexes; iRNA and epigenetic processes from DNA (2). 
 
MATERIAL AND METHODS 
 
In our study we will use new molecular diagnosis methods. The study envisages the 
understanding of early development processes and will contribute to elucidate the basic 
mechanisms determining the clinical classical modifications. Creation of a database will 
permit the collection of clinical; genetic and epigenetic from Romania and further the 
integration into the European database (3). Due to high mortality and morbidity associated 
with Prader Willi / Angelman syndromes; our study will be the ground for new clinical 
studies to establish guidelines for diagnosis and treatment; in order to improve the quality of 
medical practice and an improvement of the medical and social standard for the affected 
patients with Prader Willi/ Angelman syndromes (4). The investigation from our project is 
based on an experimental study consisting in the elaboration of working protocols; followed 
by definition of the admittance criteria. The collection of data will be done using quantitative 
(observations; routine clinical check) and qualitative (patients with PWA; opening the data 
base of the medical records for patients and relatives) methods. The protocols will be applied 
for the patients with PWA syndromes and their relatives. Blood samples will be collected for 
cytogenetic examination; using test tubes with heparin; and for molecular investigations 
using test tubes with EDTA. To the multidisciplinarity; complex evaluation of the familial 
history will be added; for establishing the admission criteria. The blood samples for the 
molecular investigations; will be performed for: DNA isolation; DNA bank custody; 
methylation specific PCR; using specific primers: usPCR for critical genes and confirmation 
of the DNA methylation profile; through sequencing the amplicons; chromatin isolation; 
ChiP test with specific covalent modified histone antibodies. 
 
RESULTS AND DISCUSIONS 
 
 Prader Willi and Angelman are two clinical; metabolic and neurological different 
syndromes with 1 case for 15000 new borns. The molecular mechanism identified in the 
early ‘90s; implied large deletions; uniparental disomia (UPD); intragenic and epigenetic 
modifications in the processes of imprinting and only rare balanced translocations. All the 
cases have in common the lose of the parental contribution necessary for normal gene 
function; in normal conditions due to genetic instability for a critical region 15q.11-q.13. 
The research for the two syndromes was extended from associated mutation detection and 
gene identification to the understanding of the mechanism which established the parental 
identity for this chromosomal region. The epigenetic mechanism proposed; implies 
alteration of the allelic parental origins specific mark by DNA methylation process. 
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 The actual studies have extended the area of epigenetic modifications; involving 
chromatin dynamic structure; through covalent modifications of histone and non-histone 
proteins. The methylation pattern respects the epigenetic silencing rule; that is: the inverse 
relation between methylation level and gene expression.  In this way; human genes have 
hypermethylated promoter and the first exon or inactive maternal allele (which has the PSW-
SRO element for imprinting control) and hypomethylated on the active allele. 
Experimental results suggest that methylation pattern represents a long time memory 
of cellular phenotype which has to be stable and capable to resist during the global 
demethylation process occurring in early embryogenesis. Chromatin components are 
presently discovered to be involved into this complex imprinting process; contributing to the 
correct preservation of the molecular mark memory and to the further de novo remethylation 
processes during the establishment of the imprinting marks in the descendent genome (5). 
For determining the sensible points of correct imprinting process; the pollution; environment 
aspects; diet and life style are now investigated.  In such circumstances; the methylation 
process not only at the DNA level but; also at the histone level plays an important role of 
signalling.  Therefore; the histone code and the corresponding specific chromatin 
remodelling programs are getting more attention when considering the complex factors of 
heredity during the reproductive process. These aspects are incomplete elucidated; and 
hypothesis must be verified through different methods of analysis.  
Knowing the epigenetic aspects from Prader-Willi/Angelman syndromes; will allow a 
more precise; rapid and correct etiological diagnosis. They can provide an adequate genetic 
counselling; avoiding recurrence of the disease; permitting an optimal management of the 
disease and a fare epigenetic therapy (6). 
A small number of cases with PWA syndromes do not fall in the aetiology described 
until today.   Our study has the great opportunity to discover new and more interesting 
aspects of these two syndromes. The genetic and epigenetic tests used for PW/A syndromes; 
and the introduction of remodelling chromatin factors study (methylation pattern at DNA 
and histone levels; as well as certain covalent modifications of histone detection) through 
immunoprecipitation method of chromatin (ChiP) and the initiation of mass spectrometry 
(MS TOF/TOF); represents the original aspect proposed by our study. The results of the 
epigenetic study will allow the correlation of the clinical; genetic and epigenetic data; and 
conclusions will be focused on the intervention possibilities on the environmental; diet 
factors; and possibly disturbance factors in the genetic imprinting process. 
Our estimated results consist in: 1. developing three methods of distinguishing the 
etiologic mechanism in PWA syndromes (the method of allelic identification through DNA 
methylation marking; remodelling chromatin factors study (histone methylation/ 
demethylation; acetylation/deacetylation) through ChiP; and detection of deletions by FISH; 
2. elaboration of a clinical/genetic /epigenetic investigation plan; for suspected PWA 
patients (5). The project will determine a research network in four reference centres for rare 
diseases; which will apply by themselves or in consortium for European projects (FP 7). 
 
CONCLUSIONS 
 
 Epigenetic research offers optimistic solutions for the early and specific testing of many 
diseases recognizing on imprinting mechanism; for the understanding of some 
incomplete known mechanisms; even for therapeutic options that may introduce certain 
control factors for the correct gene expression establishment (7). 
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 The research from Romania should be more active in the rare disease area; that's why we 
propose an epigenetic new European approach realized by prestigious teams. Through 
this new type of partnership between universities; research institutes; hospitals; 
nongovernmental associations of affected patients we try to redefine connections 
between fundamental research and the medical practice; developing a multidisciplinary 
investigation model for rare disease in Romania.  
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